In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy

G. Metro, Z. Zheng, A. Fabi, M. Schell, B. Antoniani, M. Mottolese, A. N. Monteiro, P. Vici, S. Lara Rivera, D. Boulware, F. Cognetti, G. Bepler

Research output: Contribution to journalArticle

Abstract

Ribonucleotide reductase 1 (RRM1) is a determinant of gemcitabine efficacy in non-smallcell lung cancer and pancreatic cancer. We investigated the protein levels of RRM1 and two other DNA repair enzymes, ERCC1 and BRCA1, in 55 metastatic breast cancer (MBC) patients undergoing gemcitabine-based chemotherapy. With automated in situ protein quantification (AQUA v1.6), the average scores for RRM1, ERCC1, and BRCA1 ranged from 245.6.-2774.1, 74.0-410.3, and 54.4-1833.1, respectively. They were significantly associated with each other (Spearman's rho ≥ .36; p ≤ .007). Given their pattern of distribution, RRM1 and BRCA1 are potentially suitable markers for clinical decision making in MBC.

Original languageEnglish
Pages (from-to)172-180
Number of pages9
JournalCancer Investigation
Volume28
Issue number2
DOIs
Publication statusPublished - 2010

Keywords

  • BRCA1
  • ERCC1
  • Gemcitabine
  • Metastatic breast cancer
  • RRM1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy'. Together they form a unique fingerprint.

  • Cite this